Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
IPO Year: 2021
Exchange: NASDAQ
Website: seraprognostics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2022 | $18.00 → $4.00 | Buy → Neutral | Citigroup |
| 11/19/2021 | $19.00 | Outperform | Oppenheimer |
| 10/15/2021 | Outperform | Cowen | |
| 8/9/2021 | Outperform | William Blair | |
| 8/9/2021 | Outperform | Cowen | |
| 8/9/2021 | $18.00 | Buy | Citigroup |
SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements. A live webcast of the company's presentation as well as
Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.
SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat
SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR
SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. A live webcast of the company's presentation
SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (NASDAQ:SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common
SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (NASDAQ:SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock. In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount up to an additional 15% of the total amount of shares of Class A common
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
10-Q - SERA PROGNOSTICS, INC. (0001534969) (Filer)
8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)
DEF 14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)
S-8 - SERA PROGNOSTICS, INC. (0001534969) (Filer)
10-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously
Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00
Cowen resumed coverage of Sera Prognostics with a rating of Outperform
William Blair initiated coverage of Sera Prognostics with a rating of Outperform
Cowen initiated coverage of Sera Prognostics with a rating of Outperform
Citigroup initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $18.00
SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat
SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR
SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from the prior planned date of the event due to scheduling conflicts. During the event, Sera's man
SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection wit
SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics, with coverage on front page of publication.Data analysis fo
SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2024 ended March 31, 2024. Recent Highlights: Submitted manuscript of PRIME study interim analysis results for peer-reviewed publication.Shipped first ambient whole blood collection kits, which we believe is critical to facilitating new commercial opportunities and is expected to yield s
Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same
SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the
- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors. "We are very excited to have Dr. Jane Barlow join Sera's talented board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognos
SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Sandra A. J. Lawrence has joined the Sera Board of Directors. "We are very excited to have Sandra Lawrence join the Sera board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics. "Sandra brings to Sera her broad and profound leadership experience having served on multiple public and private boards across
SALT LAKE CITY, Nov. 8, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Zhenya Lindgardt has joined the Sera Board of Directors. "We are thrilled to have Zhenya Lindgardt bring her vast and highly relevant experience to our board to improve the well-being of mothers and babies," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics, Inc. "Zhenya possesses the rare combination of d
SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs. Dr. Myers will work on a multi-disciplinary effort to execute a national and state-specific political and public affairs strategy focused on Health Equity and Disparities related to pregnancy and parturition, further emphasizing the Company's efforts to help address the healthcare disparities that disproportionately affect underserved communiti
Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Dr. Paul Kearney to the position of Chief Data Officer, effective October 1, 2021. As the chief data/analytics officer, Dr. Kearney will have responsibility to help direct, manage and analyze the large and growing data sets of Sera, both scientific and busin
SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Michael R. Foley has been appointed to the position of Chief Medical Officer beginning in January 2022. Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company™. He joins a group of talented clinical operations and medical professionals who support Sera's collaborations with research teams across the globe. "We are honored to have Dr. Foley bring his extensive Materna
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
3 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)